Caffeine Citrate Indications
Caffeine citrate is indicated for the short-term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age 1.
Primary FDA-Approved Indication
The FDA drug label clearly establishes that caffeine citrate (both IV and oral formulations) is specifically approved for treating apnea of prematurity in this narrow gestational age window 1. This represents the only formal indication with regulatory approval.
Clinical Context and Diagnosis Requirements
Before initiating caffeine citrate, apnea of prematurity must be a diagnosis of exclusion 1. You must rule out or appropriately treat other causes including:
- Central nervous system disorders
- Primary lung disease
- Anemia
- Sepsis
- Metabolic disturbances
- Cardiovascular abnormalities
- Obstructive apnea
This is critical: Starting caffeine without excluding these conditions can mask serious underlying pathology 1.
Broader Clinical Uses in Neonatal Care
While the FDA indication is narrow, guideline evidence supports additional uses in the NICU setting:
Chronic Lung Disease of Infancy (CLDI)
Caffeine is commonly used for infants with CLDI, where it improves pulmonary function and diaphragmatic contractility 2. The methylxanthine properties help relieve bronchospasm, decrease airway resistance, and increase compliance. Therapeutic serum levels should be maintained at 5-20 mg/L 2.
Periextubation Management
Research demonstrates that caffeine citrate facilitates successful extubation in preterm infants <30 weeks gestation 3. A higher maintenance dose (20 mg/kg/day vs 5 mg/kg/day) significantly reduced extubation failure (15.0% vs 29.8%) and decreased duration of mechanical ventilation in infants <28 weeks gestation 3.
Emerging Delivery Room Use
Recent guidelines discuss early caffeine administration soon after birth for preterm infants, though this requires larger prospective trials to establish effects on intubation rates, intraventricular hemorrhage, and long-term neurodevelopmental outcomes 4.
Important Contraindications and Precautions
Absolute contraindication: Hypersensitivity to any component 1.
Use with extreme caution in:
- Infants with seizure disorders (caffeine is a CNS stimulant and can precipitate seizures in overdose) 1
- Cardiovascular disease (increases heart rate, left ventricular output, and stroke volume) 1
- Impaired renal or hepatic function (requires dose adjustment and serum monitoring) 1
Dosing Considerations
Baseline serum caffeine levels must be measured before starting treatment in:
- Infants previously treated with theophylline (preterm infants metabolize theophylline to caffeine) 1
- Infants born to mothers who consumed caffeine before delivery (caffeine readily crosses the placenta) 1
Therapeutic range: 8-40 mg/L in clinical trials, though serious toxicity occurs when levels exceed 50 mg/L 1. Serum concentrations require periodic monitoring throughout treatment.
What Caffeine Citrate Is NOT Indicated For
The evidence explicitly states caffeine citrate has not been established as safe or effective for 1:
- Prophylactic treatment of sudden infant death syndrome (SIDS)
- Routine use prior to extubation in mechanically ventilated infants (though research suggests benefit, formal indication lacking)
- Treatment duration beyond 10-12 days (safety/efficacy not established for longer periods)
Common Pitfall to Avoid
Do not use caffeine citrate concurrently with theophylline—interconversion between these drugs has been reported in preterm neonates, and concurrent use is not recommended 1.